Clinical Trials at Massachusetts General Hospital

As of July 2026, 599 paid clinical trials are recruiting at Massachusetts General Hospital, located at Faustman Lab at Massachusetts General Hospital, 149 13th St #3602, Boston, MA 02129, phone (617) 726-4084 in Boston, Massachusetts. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

604 clinical trials at Massachusetts General Hospital

·Clear filters·↓ Download CSV

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

for Metastatic Solid Tumor

Drug: LY4052031

18 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06465069·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

for NSCLC

Drug: EP0031

21 locations incl. Los Angeles

Sponsor: Ellipses Pharma

Sex: All·Age: 18+

Code: NCT05443126·Phase 1, Phase 2·Recruiting·Listed Jul 2022

Apply to this trial

A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta

for Aortic Aneurysm

15 locations incl. Los Angeles

Sponsor: Vascutek Ltd.

Sex: All·Age: 18+

Code: NCT07078383·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

for Autoimmune Haemolytic Anaemia

23 locations incl. Phoenix

Sponsor: Sanofi

Sex: All·Age: 18+

Code: NCT07086976·Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

for Immune Thrombocytopenic Purpura (ITP)

17 locations incl. Los Angeles

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT06948318·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Drug: Cemiplimab

24 locations incl. Gilbert

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT03972657·Phase 1, Phase 2·Recruiting·Listed Jun 2019

Apply to this trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

for Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer

12 locations incl. Duarte

Sponsor: Hoffmann-La Roche

Sex: Female·Age: 18+

Code: NCT04802759·Phase 1, Phase 2·Recruiting·Listed Mar 2021

Apply to this trial

4D-710 in Adult Patients With Cystic Fibrosis

for Cystic Fibrosis Lung

20 locations incl. Birmingham

Sponsor: 4D Molecular Therapeutics

Sex: All·Age: 18+

Code: NCT05248230·Phase 2·Recruiting·Listed Feb 2022

Apply to this trial

Study of HLD-0915 in Patients With Metastatic Prostate Cancer

for Metastatic Prostate Cancer

11 locations incl. Denver

Sponsor: Halda Therapeutics OpCo, Inc.

Sex: Male·Age: 18+

Code: NCT06800313·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

for Treatment Resistant Depression

24 locations incl. Birmingham

Sponsor: Abbott Medical Devices

Sex: All·Age: 22 - 70

Code: NCT06423430·Recruiting·Listed May 2024

Apply to this trial

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

for Ovarian Cancer

21 locations incl. Birmingham

Sponsor: Regeneron Pharmaceuticals

Sex: Female·Age: 18+

Code: NCT06787612·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

for Small Cell Lung Cancer (SCLC)

15 locations incl. Duarte

Sponsor: Phanes Therapeutics

Sex: All·Age: 18+

Code: NCT05652686·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

for Immune Thrombocytopenic Purpura (ITP)

18 locations incl. Los Angeles

Sponsor: Takeda

Sex: All·Age: 18+

Code: NCT06722235·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

for Mesial Temporal Lobe Epilepsy

18 locations incl. Birmingham

Sponsor: UniQure Biopharma B.V.

Sex: All·Age: 18 - 75

Code: NCT06063850·Phase 1, Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

for Non-small Cell Lung Cancer (NSCLC)

17 locations incl. Sacramento

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06040541·Phase 1·Recruiting·Listed Sep 2023

Apply to this trial

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

for Chronic Neuropathic Pain

11 locations incl. Scottsdale

Sponsor: Sangamo Therapeutics

Sex: All·Age: 18+

Code: NCT06980948·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

for Non-Small Cell Lung Cancer

16 locations incl. Los Angeles

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06917079·Phase 1·Recruiting·Listed Apr 2025

Apply to this trial

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

for IC-MPGN

Drug: Iptacopan

22 locations incl. Los Angeles

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 12 - 60

Code: NCT05755386·Phase 3·Recruiting·Listed Mar 2023

Apply to this trial

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

for Crohn's Disease

Drug: Risankizumab

11 locations incl. Phoenix

Sponsor: AbbVie

Sex: All·Age: 2 - 17

Code: NCT05995353·Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

for Pheochromocytoma/Paraganglioma

14 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 12+

Code: NCT04924075·Phase 2·Recruiting·Listed Jun 2021

Apply to this trial

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma

13 locations incl. San Francisco

Sponsor: K36 Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05651932·Phase 1·Recruiting·Listed Dec 2022

Apply to this trial

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

for Diabetes Mellitus, Type 1

12 locations incl. Duarte

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 18 - 65

Code: NCT04786262·Phase 3·Recruiting·Listed Mar 2021

Apply to this trial

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

for Solid Tumor, Adult

19 locations incl. Duarte

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06625775·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

for Unresectable Head and Neck Squamous Cell Carcinoma

19 locations incl. Los Angeles

Sponsor: BioNTech SE

Sex: All·Age: 18+

Code: NCT04534205·Phase 2, Phase 3·Recruiting·Listed Sep 2020

Apply to this trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

for PDAC

18 locations incl. Scottsdale

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06922591·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

for NSCLC (Advanced Non-small Cell Lung Cancer)

24 locations incl. Phoenix

Sponsor: BlossomHill Therapeutics

Sex: All·Age: 18+

Code: NCT06706076·Phase 1, Phase 2·Recruiting·Listed Nov 2024

Apply to this trial

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

for Locally Advanced Solid Tumor

21 locations incl. Orange

Sponsor: Nuvalent Inc.

Sex: All·Age: 12+

Code: NCT05384626·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

for Pancreatic Ductal Adenocarcinoma

13 locations incl. Los Angeles

Sponsor: Verastem, Inc.

Sex: All·Age: 18+

Code: NCT07020221·Phase 1, Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth in/Near Infected Bone Cavities

for Periprosthetic Joint Infections

16 locations incl. Los Angeles

Sponsor: Elute, Inc.

Sex: All·Age: 22+·Accepts healthy volunteers

Code: NCT05361941·Recruiting·Listed May 2022

Apply to this trial

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

for Advanced Solid Tumors

16 locations incl. Los Angeles

Sponsor: ModernaTX, Inc.

Sex: All·Age: 12+

Code: NCT05533697·Phase 1, Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

for Pancreatic Ductal Adenocarcinoma

9 locations incl. Birmingham

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT06562192·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

for Refractory Cancer

Drug: Nivolumab

13 locations incl. Stanford

Sponsor: Immatics US, Inc.

Sex: All·Age: 18+

Code: NCT03686124·Phase 1, Phase 2·Recruiting·Listed Sep 2018

Apply to this trial

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

for Primary Myelofibrosis

13 locations incl. Palo Alto

Sponsor: Ajax Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06343805·Phase 1·Recruiting·Listed Apr 2024

Apply to this trial

A Study of PYX-201 in Advanced Solid Tumors

for Solid Tumor

17 locations incl. Scottsdale

Sponsor: Pyxis Oncology, Inc

Sex: All·Age: 18+

Code: NCT05720117·Phase 1·Recruiting·Listed Feb 2023

Apply to this trial

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

for Generalized Myasthenia Gravis

Drug: Iptacopan

21 locations incl. Scottsdale

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 85

Code: NCT06517758·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

for Systemic Lupus Erythematosus

Drug: Inebilizumab

17 locations incl. Scottsdale

Sponsor: Amgen

Sex: All·Age: 18 - 75

Code: NCT06570798·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

for Advanced Solid Tumors

11 locations incl. San Diego

Sponsor: Pyxis Oncology, Inc

Sex: All·Age: 18+

Code: NCT06795412·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

for Rheumatoid Arthritis (RA)

10 locations incl. San Francisco

Sponsor: Sonoma Biotherapeutics, Inc.

Sex: All·Age: 18 - 71

Code: NCT07123038·Recruiting·Listed Aug 2025

Apply to this trial

The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).

for Intracranial Aneurysm

23 locations incl. Englewood

Sponsor: Medtronic Neurovascular Clinical Affairs

Sex: All·Age: 18 - 75

Code: NCT02998229·Recruiting·Listed Dec 2016

Apply to this trial

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

for Metastatic Solid Tumor

17 locations incl. Santa Monica

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06561685·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial